On Monday, June 1, ENDECE presented the following abstract to the Michael, Marcia, and Christa Parseghian Scientific Conference for NPC Research | Virtual Symposiums NDC-1308: A novel anti-inflammatory and remyelinating therapeutic in late pre-clinical studies for...
ENDECE’s lead clinical development candidate, NDC-1308 (MC1) could prove to be an important therapeutic option in minimizing respiratory failure in COVID-19 patients caused by the SARS-CoV-2 virus health emergency and global pandemic.ENDECE’s Research Effort to Treat...
